Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Phase:
PHASE1
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborators:
Belfast Health and Social Care Trust Cambridge University Hospitals NHS Foundation Trust Institute of Oncology Research (IOR) Janssen Pharmaceutica N.V., Belgium Oncology Institute of Southern Switzerland Prostate Cancer UK Royal Marsden NHS Foundation Trust Syntrix Biosystems, Inc.